REGULUS THERAPEUTICS INC (RGLS) Stock Income Statement
NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 51.75M | 50.04M | 31.11M | 28.24M | 27.82M | |||
| Research and Development | 35.94M | 35.37M | 21.01M | 18.31M | 17.35M | |||
| Selling, General, and Administrative Expenses | 15.61M | 14.67M | 9.96M | 9.83M | 10.02M | |||
| Operating Income | -51.75M | -50.04M | -31.11M | -28.24M | -27.82M | |||
| Interest Income/Expense | 4.23M | 3.68M | 1.07M | -83.00K | 9.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -47.52M | -46.36M | -30.04M | -28.32M | -27.81M | |||
| Income Tax | N/A | 1.00K | 1.00K | 1.00K | 1.00K | |||
| Net Income | -47.52M | -46.36M | -30.04M | -28.32M | -27.81M | |||
| EBITDA | -51.40M | -49.69M | -30.88M | -28.12M | -27.36M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.73 | -0.82 | -1.58 | -1.86 | -3.24 | |||
| Non GAAP EPS | -0.73 | -0.87 | -1.59 | -1.90 | -3.30 | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
| Operating Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
All data in USD